- Home
- CYRX vs MREO Comparison
CYRX vs MREO Comparison
Compare CYRX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | MREO |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.7M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYRX | MREO |
|---|---|---|
| Price | $9.26 | $2.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $12.83 | $7.50 |
| AVG Volume (30 Days) | 590.7K | ★ 2.2M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $243,795,000.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.26 | $131.12 |
| P/E Ratio | $7.43 | ★ N/A |
| Revenue Growth | ★ 41.27 | N/A |
| 52 Week Low | $4.58 | $1.47 |
| 52 Week High | $11.44 | $3.90 |
Technical Indicators
Market Signals| Indicator | CYRX | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 57.94 |
| Support Level | $9.08 | $2.02 |
| Resistance Level | $10.30 | $2.37 |
| Average True Range (ATR) | 0.44 | 0.15 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 13.71 | 61.11 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).